All In Biotech

Free tool

FAERS Monitor: Ruby-Fill

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202153 or its brand name (Ruby-Fill, Rubidium Chloride Rb-82). Reports on generic versions are filed under their own applications.

Reports

15

Serious

0

0% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective6
  • underdose6
  • product preparation error5
  • device use error2
  • incorrect dose administered by device2
  • back pain1
  • decreased appetite1
  • headache1
  • lip swelling1
  • pain1
  • paraesthesia1
  • product delivery mechanism issue1
  • renal pain1
  • sleep disorder1

Reports by year received

View as table
YearReports
20193
20202
20211
20225
20234

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,144 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product preparation errorSignal5341.3166.81,374
product delivery mechanism issue1260.839.364
renal pain1132.319.932
underdoseSignal6115.362.0572
incorrect dose administered by device2107.029.4118
device use error280.722.288
lip swelling142.16.310
sleep disorder119.93.04
paraesthesia18.91.31
drug ineffectiveSignal66.43.424
decreased appetite16.00.91
back pain16.00.91
pain12.30.30
headache12.20.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.